MedPath

Mindfulness-Based Cognitive Therapy (MBCT) and Cognitive Behavioral Therapy (CBT) for Depression in Diabetes Patients

Not Applicable
Completed
Conditions
Depressive Symptoms
Interventions
Behavioral: Cognitive Behavioral Therapy (CBT)
Behavioral: Mindfulness-Based Cognitive Therapy (MBCT)
Registration Number
NCT01630512
Lead Sponsor
University Medical Center Groningen
Brief Summary

The purpose of this study is to determine whether mindfulness-based cognitive therapy (MBCT)and cognitive behavioral therapy (CBT)are effective in reducing depressive symptoms in patients with diabetes.

Detailed Description

Depression is a common co-morbidity of diabetes, negatively affecting physical performance, glycemic control, adherence to medication, and dietary, and exercise recommendations. Modalities of psychotherapy like cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) can reduce depressive symptoms in patients with medical conditions. However, proper designed randomized trials assessing and comparing effectiveness of these psychological interventions are rare.

This longitudinal study aims to investigate the effectiveness of CBT and MBCT in reducing depressive symptoms in diabetes patients. Furthermore, potential moderators and mediators of treatment effect will be explored, as well as the role of common factors and treatment integrity.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
94
Inclusion Criteria
  • Diabetes mellitus Type 1 or 2 for at least three months prior to inclusion
  • Written informed consent
  • Age ≥ 18 and ≤ 70
  • Depressive symptoms as assessed by BDI-II score ≥ 14 (cut-off score indicating the presence of at least mild symptoms of depression)
Exclusion Criteria
  • Not being able to read and write Dutch
  • Severe (psychiatric) co-morbidity
  • Acute suicidal ideations or behavior
  • Pregnancy
  • Receiving an alternative psychological treatment during or less than two months prior to starting the participation in the study

Using an antidepressant drug during participation in the present study is allowed, on condition that a patient has been on stable medication regimen for at least two months prior to inclusion in the study, and that no new treatment with an antidepressant is initiated during the course of the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CBTCognitive Behavioral Therapy (CBT)-
MBCTMindfulness-Based Cognitive Therapy (MBCT)-
Primary Outcome Measures
NameTimeMethod
change in severity of depressive symptomschange from baseline in severity of depressive symptoms at 3 months, 6 months, and 12 months

severity of depressive symptoms will be assessed with the Beck Depression Inventory-II

Secondary Outcome Measures
NameTimeMethod
change in depressive symptomschange from baseline in depressive symptoms at 3 months, 6 months, and 12 months

depressive symptoms will be measured by the 7-Item Hamilton Depression Rating scale (HAM-D7)

change in generalized anxietychange from baseline in generalized anxiety at 3 months, 6 months, and 12 months

generalized anxiety will be measured by the Generalised Anxiety Disorder Assessment (GAD 7)

intersession changes in moodchange in mood from the beginning of the first session to the beginning of the last session

intersession changes in mood will be assessed by the Emotion Thermometers Tool (ETT)

change in diabetes related distresschange from baseline in diabetes related distress at 3 months, 6 months, and 12 months

diabetes related distress will be measured by the Problem Areas in Diabetes scale (PAID)

change in well-beingchange from baseline in well-being at 3 months, 6 months, and 12 months

well-being will be measured by the Well-being Index (WHO-5)

change in glycemic controlchange from baseline in glycemic control at post-treatment

glycemic control will be indicated with HbA1c values

Trial Locations

Locations (1)

UMCG

🇳🇱

Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath